177
Views
65
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

MMP-9 (Gelatinase B) Expression is Associated With Disease-Free Survival and Disease-Specific Survival in Colorectal Cancer Patients

, , , , , , & show all
Pages 38-43 | Published online: 09 Dec 2009

REFERENCES

  • Chambers, A.F.; Matrisian, L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89(17), 1260–1270.
  • Coussens, L.M.; Werb, Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996, 3, 895–904.
  • Kelly, T.; Yan, Y.; Osborne, R.L.; Athota, A.B.; Rozypal, T.L.; Colclasure, J.C.; Chu, W.S. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 1998, 16, 501–512.
  • Nikkola, J.; Vihinen, P.; Vlaykova, T.; Hahka-Kemppinen, M.; Kahari, V.M.; Pyrhonen, S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002, 97, 432–438.
  • Kahari, V.M.; Saarialho-Kere, U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999, 31, 34–45.
  • Kleiner, D.E.; Stetler-Stevenson, W.G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, 43, 42–51.
  • Liotta, L.A.; Tryggvason, K.; Garbisa, S.; Hart, I.; Foltz, C.M.; Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284, 67–68.
  • Yamaguchi, A.; Kurosaka, Y.; Ishida, T.; Nishimura, G.; Kanno, M.; Kosaka, T.; Yonemura, Y.; Miyazaki, I. Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 1991, 34, 921–924.
  • Inoue, T.; Yashiro, M.; Nishimura, S.; Maeda, K.; Sawada, T.; Ogawa, Y.; Sowa, M.; Chung, K.H. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 1999, 4, 73–77.
  • Murray, G.I.; Duncan, M.E.; O'Neil, P.; Melvin, W.T.; Fothergill, J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996, 2, 461–462.
  • Ito, T.; Ito, M.; Shiozawa, J.; Naito, S.; Kanematsu, T.; Sekine, I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999, 12, 669–674.
  • Grigioni, W.F.; D'Errico, A.; Fortunato, C.; Fiorentino, M.; Mancini, A.M.; Stetler-Stevenson, W.G.; Sobel, M.E.; Liotta, L.A.; Onisto, M.; Garbisa, S. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 1994, 7, 220–225.
  • Miyajima, Y.; Nakano, R.; Morimatsu, M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995, 104, 678–684.
  • Westerlund, A.; Apaja-Sarkkinen, M.; Hoyhtya, M.; Puistola, U.; Turpeenniemi-Hujanen, T. Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999, 75, 91–98.
  • Passlick, B.; Sienel, W.; Seen-Hibler, R.; Wockel, W.; Thetter, O.; Mutschler, W.; Pantel, K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000, 6, 3944–3948.
  • Davidson, B.; Goldberg, I.; Kopolovic, J.; Lerner-Geva, L.; Gotlieb, W.H.; Ben-Baruch, G.; Reich, R. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma–a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999, 73, 372–382.
  • Talvensaari-Mattila, A.; Paakko, P.; Hoyhtya, M.; Blanco-Sequeiros, G.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998, 83, 1153–1162.
  • Murray, D.; Morrin, M.; McDonnell, S. Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 2004, 24, 489–494.
  • Unsal, D.Akyurek, N.; Uner, A.; Erpolat, O.P.; Han, U.; Akmansu, M.; Mentes, B.B.; Dursun, A. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol 2008, 31, 55–63.
  • Zeng, Z.S.; Huang, Y.; Cohen, A.M.; Guillem, J.G. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996, 14, 3133–3140.
  • Ring, P.; Johansson, K.; Hoyhtya, M.; Rubin, K.; Lindmark, G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer–a predictor of tumour stage. Br J Cancer 1997, 76, 805–811.
  • Bufill, J.A. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990, 113, 779–788.
  • Bleeker, W.A.; Hayes, V.M.; Karrenbeld, A.; Hofstra, R.M.; Hermans, J.; Buys, C.C.; Plukker, J.T. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol 2000, 95, 2953–2957.
  • Elsaleh, H.; Joseph, D.; Grieu, F.; Zeps, N.; Spry, N.; Iacopetta, B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355, 1745–1750.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.